You are here
CURE Pharmaceutical to Showcase Company Growth at the 8th LD Micro Invitational
Webcast available 15 minutes after presentation on June 4th
LOS ANGELES, May 23, 2018 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced that it will be presenting at the 8th annual LD Micro Invitational on Monday, June 4th at 4 PM PT/ 7 PM ET at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. CEO Rob Davidson will be presenting and meeting with investors.
“We are at a critical inflection point in our business with product launches and increased manufacturing capabilities,” said Rob Davidson, CEO of CURE Pharmaceutical. “It’s the perfect time for the investment community to hear how CURE is leading the way in the pharmaceutical industry’s innovation revolution.”
Davidson will be highlighting the company’s Q1 accomplishments including new partnerships, plans for future strategic growth and strides it has made in endocannabinoid research. He will also be discussing the expanding product pipeline that leverages CURE Pharmaceutical’s patented CUREFilm™ technology, one of the most advanced oral thin film on the market today.
CURE's presentation will be webcast and archived until June 4, 2019. Those wishing to access the presentation can do so by logging on to http://wsw.com/webcast/ldmicro14/curr/ shortly after.
The conference will feature 230 companies in the small-cap / micro-cap space and will be attended by over 1,000 individuals. View CURE Pharmaceutical’s profile here: https://www.ldmicro.com/profile/CURR.
CURE Pharmaceutical will be hosting meetings at the following upcoming events:
- 2018 BIO International Convention – June 4th – 6th in Boston, MA
- O’Canna Biz Conference & Expo – June 7th – 9th in Toronto
- CannX International Medical Cannabis Conference – October 14th – 16th in Tel Aviv
If you would like to schedule a meeting with CURE Pharmaceutical, please contact Ashley Ray at email@example.com.
About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. The firm hosts several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.
This press release contains forward-looking statements that involve risks and uncertainties. There are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the ability to successfully market our products, the difficulty in predicting the timing or outcome of other product research and development efforts, potential product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Olmstead Williams Communications